MA52154B1 - Composition pharmaceutique pour l'anémie - Google Patents

Composition pharmaceutique pour l'anémie

Info

Publication number
MA52154B1
MA52154B1 MA52154A MA52154A MA52154B1 MA 52154 B1 MA52154 B1 MA 52154B1 MA 52154 A MA52154 A MA 52154A MA 52154 A MA52154 A MA 52154A MA 52154 B1 MA52154 B1 MA 52154B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
anemia
relates
formulation
aoi
Prior art date
Application number
MA52154A
Other languages
English (en)
Other versions
MA52154A (fr
Inventor
Vedprakash Mishra
Ankit Shyam Singh
Neelima Tongra
Original Assignee
Frimline Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frimline Private Ltd filed Critical Frimline Private Ltd
Publication of MA52154A publication Critical patent/MA52154A/fr
Publication of MA52154B1 publication Critical patent/MA52154B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition/formulation pharmaceutique destinée à être utilisée dans le traitement de l'anémie ferriprive (ida), de l'anémie d'inflammation (aoi) et de troubles neuro-dégénératifs. Plus particulièrement, l'invention concerne une composition/formulation pharmaceutique comprenant une combinaison synergique de lactoferrine et de nucléotides de guanosine ou d'un sel pharmaceutiquement acceptable de celle-ci. L'invention concerne également diverses formulations et leurs procédés de préparation.
MA52154A 2018-03-09 2019-03-04 Composition pharmaceutique pour l'anémie MA52154B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821008809 2018-03-09
PCT/IB2019/051706 WO2019171236A1 (fr) 2018-03-09 2019-03-04 Composition pharmaceutique pour l'anémie

Publications (2)

Publication Number Publication Date
MA52154A MA52154A (fr) 2020-06-10
MA52154B1 true MA52154B1 (fr) 2022-09-30

Family

ID=66397286

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52154A MA52154B1 (fr) 2018-03-09 2019-03-04 Composition pharmaceutique pour l'anémie

Country Status (24)

Country Link
US (1) US12016906B2 (fr)
EP (1) EP3661373B1 (fr)
AU (1) AU2019232621B2 (fr)
BR (1) BR112020018319A2 (fr)
CA (1) CA3073184C (fr)
CO (1) CO2020010193A2 (fr)
DK (1) DK3661373T3 (fr)
EA (1) EA202090276A1 (fr)
ES (1) ES2927216T3 (fr)
HR (1) HRP20221105T1 (fr)
HU (1) HUE059584T2 (fr)
LT (1) LT3661373T (fr)
MA (1) MA52154B1 (fr)
MD (1) MD3661373T2 (fr)
MY (1) MY183462A (fr)
PE (1) PE20201278A1 (fr)
PH (1) PH12019550263A1 (fr)
PL (1) PL3661373T3 (fr)
PT (1) PT3661373T (fr)
RS (1) RS63563B1 (fr)
SG (1) SG11202008732VA (fr)
SI (1) SI3661373T1 (fr)
UA (1) UA123852C2 (fr)
WO (1) WO2019171236A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202020101861U1 (de) * 2020-04-06 2020-04-16 artgerecht GmbH Eisen-enthaltende Formulierung, ernährungsphysiologische Zusammensetzung, welche diese enthält, und Verwendung derselben
IT202000012373A1 (it) * 2020-05-26 2021-11-26 Prosol S P A Formulazione farmaceutica o di integratore alimentare per l’uso nel trattamento di disturbi dovuti alla carenza di ferro
IT202000022003A1 (it) * 2020-09-18 2022-03-18 Difass Int S R L Composizioni comprendenti un sale minerale per uso orale
WO2022118274A1 (fr) * 2020-12-03 2022-06-09 Neilos S.r.l. Compositions destinées à être utilisées dans le traitement et/ou la prévention d'états ou de maladies de carence en fer
CN118524831A (zh) * 2021-12-03 2024-08-20 帝斯曼知识产权资产管理有限公司 用于维生素c的新递送系统
CN114392249B (zh) * 2022-01-13 2023-09-12 上海医药集团青岛国风药业股份有限公司 一种多糖铁复合物的肠溶微丸及粉末直压片剂
WO2024097926A1 (fr) * 2022-11-03 2024-05-10 Nutrition & Biosciences Usa 1, Llc Système d'administration orale de macromolécule biologique
CN116530687A (zh) * 2023-06-03 2023-08-04 重庆医科大学 一种含乳酸亚铁口服溶液及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022052A1 (en) 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
CN1218647C (zh) * 2003-04-03 2005-09-14 石家庄三鹿集团股份有限公司 新生婴儿奶粉
WO2007022537A2 (fr) 2005-08-19 2007-02-22 Agennix Incorporated Utilisation de lactoferrine en tant que chémokine et modulateur chimiotactique
CA2771283A1 (fr) 2009-08-13 2011-02-17 Nestec S.A. Compositions nutritionnelles comprenant des nucleotides exogenes
WO2016073132A1 (fr) * 2014-11-07 2016-05-12 Mjn U.S. Holdings Llc Compositions nutritionnelles contenant un prébiotique et de la lactoferrine et leurs utilisations
CA3030022A1 (fr) 2016-07-06 2018-01-11 Building Block Nutritionals, Llc Formule nutritionnelle
CN106578134A (zh) 2016-12-31 2017-04-26 东北农业大学 一种预防感染性腹泻的婴儿配方奶粉
CN107549612B (zh) * 2017-09-12 2021-01-12 东北农业大学 一种提高6-12个月龄婴儿免疫力的营养配方米粉

Also Published As

Publication number Publication date
AU2019232621B2 (en) 2020-10-08
CO2020010193A2 (es) 2020-08-31
EP3661373A1 (fr) 2020-06-10
US12016906B2 (en) 2024-06-25
SG11202008732VA (en) 2020-10-29
MY183462A (en) 2021-02-18
PH12019550263A1 (en) 2021-01-11
UA123852C2 (uk) 2021-06-09
HRP20221105T1 (hr) 2022-11-25
LT3661373T (lt) 2022-09-26
HUE059584T2 (hu) 2022-11-28
RS63563B1 (sr) 2022-10-31
ES2927216T3 (es) 2022-11-03
DK3661373T3 (da) 2022-09-12
CA3073184C (fr) 2021-11-16
SI3661373T1 (sl) 2022-10-28
PL3661373T3 (pl) 2022-10-03
AU2019232621A1 (en) 2020-03-12
WO2019171236A1 (fr) 2019-09-12
EA202090276A1 (ru) 2020-11-16
EP3661373B1 (fr) 2022-06-22
PE20201278A1 (es) 2020-11-24
US20200405822A1 (en) 2020-12-31
MD3661373T2 (ro) 2022-11-30
MA52154A (fr) 2020-06-10
BR112020018319A2 (pt) 2020-12-29
PT3661373T (pt) 2022-09-22
CA3073184A1 (fr) 2019-09-12

Similar Documents

Publication Publication Date Title
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
MA53076B1 (fr) Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA34002B1 (fr) Thérapie antivirale
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA34553B1 (fr) Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MX2021002902A (es) Composicion farmaceutica para prevenir o tratar la enfermedad del higado graso no alcoholico, que contiene ligando gpr119 como principio activo.
MA38694A2 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA39421A (fr) Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA49396B1 (fr) Traitement de la migraine avec acétyl-leucine
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
MA58507A1 (fr) Composition pharmaceutique aqueuse de levilimab
MA41102A (fr) Compositions contenant de la curcumine à biodisponibilité améliorée